NCT00857259 - The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

July 31, 2010

Conditions

Choroidal Neo-Vascular Age-onset Macular DegenerationAge-related Macular Degeneration

Interventions

DRUG

Everolimus

5 mg oral tablet

DRUG

Ranibizumab

0.5 mg administered by intravitreal injection

Trial Locations (12)

Discover Vision Center, Independence

Porter Adventist Hospital, Diagnostic Eye Laboratory, Denver

Retina-Vitreous Associates Medical Group, Beverly Hills

Retinal Consultants Medical Group, Inc., Sacramento

Novartis Investigative Site, Bristol

Novartis Investigative Site, Frimley

Novartis Investigative Site, Liverpool

Novartis Investigative Site, London

Novartis Investigative Site, Oxford

Novartis Investigative site, Portsmouth

Novartis Investigative Site, Southampton

Novartis Investigator Site, Wolverhampton